Jun. 25 at 4:21 PM
$XBI this is the one
$PGEN has transformed we need to talk about it. This all happened in the last few months.
✅ First and only FDA-approved treatment for adult RRP (PAPZIMEOS)
✅ Q1 2026 product revenue of
$21.6M, beating expectations
✅ Total Q1 2026 revenue of
$23.3M
✅ Net loss reduced from -
$54M to -
$8M
✅ Management expects cash-flow breakeven by the end of 2026
✅ CMS assigned permanent J-code J3404
✅ Insurance coverage expanded to 297 million insured lives
✅ FDA granted 7 years of Orphan Drug Exclusivity through 2032
✅ New clinical data shows responses lasting more than 4 years
✅ Is now being prescribed nationwide at both major medical centers
✅ EMA marketing application currently under review for Europe
✅ HC Wainwright raised its price target from
$11 to
$14 while
✅ Approximately 21–25% short interest
